JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s Ministry of Food and Drug...
Search results for "obesity drug"
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival
Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival compound in reducing visceral fat...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs
As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less
"First I’ll lose the weight, and then I’ll start exercising."It is a thought shared by almost anyone starting highly...
HK inno.N’s Obesity Drug Candidate Outperforms Wegovy in Head-to-Head Phase 2 Trial
HK inno.N announced on June 9 that its obesity drug candidate, ecnoglutide, demonstrated superior weight-loss efficacy...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone
GLP-1 receptor agonists like Wegovy and Mounjaro have fundamentally reshaped the treatment of diabetes and obesity.